Communiqués Protagonist Therapeutics, Inc.

Actions

PTGX

US74366E1029

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
28,15 ^USD	+1,55 %		-7,43 %	+22,76 %

07/05	Protagonist Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
03/04	Un initié de Protagonist Therapeutics a vendu des actions d'une valeur de 707 750 $, selon un récent dépôt auprès de la SEC	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Protagonist Therapeutics: Q1 Earnings Snapshot	07/05	AQ
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	27/03	AQ
Protagonist Therapeutics: Q4 Earnings Snapshot	27/02	AQ
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	30/01	AQ
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	13/12	AQ
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib	28/11	AQ
Protagonist Therapeutics: Q3 Earnings Snapshot	02/11	AQ
Protagonist Announces Advancement of JNJ-2113 across Multiple Indications	10/10/23	AQ
Protagonist Therapeutics to Present at Upcoming Investor Conferences	06/09/23	AQ
Protagonist Receives $34 Million from Warrant Exercises	10/08/23	AQ
Protagonist Therapeutics Reports Granting of Inducement Award	19/07/23	AQ
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	15/05/23	AQ
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	12/05/23	PR
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference	11/05/23	PR
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association	11/05/23	PR
Protagonist Therapeutics: Q1 Earnings Snapshot	04/05/23	AQ
PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	04/05/23	AQ
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update	04/05/23	PR
Protagonist Therapeutics : Underwriting Agreement - Form 8-K	10/04/23	PU
PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)	10/04/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Protagonist Therapeutics, Inc.

Actions

PTGX

US74366E1029

Communiqués

Filtres